CLDN1 and head and neck cancer: Currently, there is an ongoing clinical trial that evaluated the efficacy and safety of ALE.C04 in monotherapy (first-in-class anti-claudin-1 monoclonal antibody) and combination with pembrolizumab (anti-PD-L1) in head and neck cancer (NCT06054477).